Attaya Suvannasankha, MD, discusses future research directions with bispecific antibodies in patients with multiple myeloma and potential methods for mitigating adverse effects in this population.
As part of an effort to increase antibody efficacy, bispecific antibodies (bsAbs), which can bind two different antigens or epitopes are becoming an area of focus. Most bsABs in trial are cancer therapeutics and this article delves into their potential usage in cancer immunotherapy.
Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.